Treatment for unresectable or metastatic oesophageal cancer: current evidence and trends

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Nature reviews: Gastroenterology & hepatology

• Publication date

  2018-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1038/nrgastro.2017.162PMID 29235549
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Chemotherapy for advanced gastric cancer.

  2017cited by this paper
• Integrated genomic characterization of oesophageal carcinoma

  2017cited by this paper
• Oesophageal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

  2016cited by this paper
• A randomized, open-label, multicenter, adaptive phase 2/3 study of trastuzumab emtansine (T-DM1) versus a taxane (TAX) in patients (pts) with previously treated HER2-positive locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma (LA/MGC/GEJC).

  2016cited by this paper
• Phase II study of nivolumab (ONO-4538/BMS-936558) in patients with esophageal cancer: Preliminary report of overall survival.

  2016cited by this paper
• Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC--A Randomized Phase III Trial.

  2016cited by this paper
• The efficacy and safety of S-1-based regimens in the first-line treatment of advanced gastric cancer: a systematic review and meta-analysis

  2016cited by this paper
• Updated results for the advanced esophageal carcinoma cohort of the phase 1b KEYNOTE-028 study of pembrolizumab.

  2016cited by this paper
• The Incremental Value of Subjective and Quantitative Assessment of 18F-FDG PET for the Prediction of Pathologic Complete Response to Preoperative Chemoradiotherapy in Esophageal Cancer

  2016cited by this paper
• Encouraging results for PD-1 inhibition in gastric cancer.

  2016cited by this paper
• Endoscopic biopsy and EUS for the detection of pathologic complete response after neoadjuvant chemoradiotherapy in esophageal cancer: a systematic review and meta-analysis.

  2016cited by this paper
• CALGB 80403 (Alliance)/E1206: A Randomized Phase II Study of Three Chemotherapy Regimens Plus Cetuximab in Metastatic Esophageal and Gastroesophageal Junction Cancers.

  2016cited by this paper
• The value of secondary pathology review.

  2016cited by this paper
• Prognosis and Treatment After Diagnosis of Recurrent Esophageal Carcinoma Following Esophagectomy with Curative Intent

  2015cited by this paper
• Optimal first-line chemotherapeutic treatment in patients with locally advanced or metastatic esophagogastric carcinoma: triplet versus doublet chemotherapy: a systematic literature review and meta-analysis

  2015cited by this paper
• Imaging of oesophageal cancer with FDG-PET/CT and MRI.

  2015cited by this paper
• Diffusion-weighted magnetic resonance imaging for the prediction of pathologic response to neoadjuvant chemoradiotherapy in esophageal cancer.

  2015cited by this paper
• Definitive chemoradiation for patients with inoperable and/or unresectable esophageal cancer: locoregional recurrence pattern.

  2015cited by this paper
• Liver Resection for Non-Colorectal, Non-Carcinoid, Non-Sarcoma Metastases: A Multicenter Study

  2015cited by this paper
• Clinicopathological factors predicting R0 resection and long-term survival after esophagectomy in patients with T4 esophageal cancer undergoing induction chemotherapy or chemoradiotherapy

  2015cited by this paper
• Esophageal and esophagogastric junction cancers, version 1.2015.

  2015cited by this paper
• Randomized multicenter phase III study of a modified docetaxel and cisplatin plus fluorouracil regimen compared with cisplatin and fluorouracil as first-line therapy for advanced or locally recurrent gastric cancer

  2015cited by this paper
• A Meta-Analysis of Concurrent Chemoradiotherapy for Advanced Esophageal Cancer

  2015cited by this paper
• Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012

  2015cited by this paper
• Phase III, randomized, double-blind, multicenter, placebo (P)-controlled trial of rilotumumab (R) plus epirubicin, cisplatin and capecitabine (ECX) as first-line therapy in patients (pts) with advanced MET-positive (pos) gastric or gastroesophageal junction (G/GEJ) cancer: RILOMET-1 study.

  2015cited by this paper
• High-dose versus conventional-dose irradiation in cisplatin-based definitive concurrent chemoradiotherapy for esophageal cancer: a systematic review and pooled analysis

  2015cited by this paper
• The rise in metastasectomy across cancer types over the past decade

  2015cited by this paper
• Point-of-care testing in the diagnosis of gastrointestinal cancers: current technology and future directions.

  2015cited by this paper
• Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial.

  2014cited by this paper
• Interventions for dysphagia in oesophageal cancer.

  2014cited by this paper
• Palliative radiotherapy in addition to self-expanding metal stent for improving dysphagia and survival in advanced oesophageal cancer (ROCS: Radiotherapy after Oesophageal Cancer Stenting): study protocol for a randomized controlled trial

  2014cited by this paper
• Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study.

  2014cited by this paper
• Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial.

  2014cited by this paper
• Hospital of diagnosis and probability to receive a curative treatment for oesophageal cancer.

  2014cited by this paper
• Potential benefits of early nutritional intervention in adults with upper gastrointestinal cancer: a pilot randomised trial

  2014cited by this paper
• Bevacizumab plus capecitabine and cisplatin in Chinese patients with inoperable locally advanced or metastatic gastric or gastroesophageal junction cancer: randomized, double-blind, phase III study (AVATAR study)

  2014cited by this paper
• Intraluminal brachytherapy in oesophageal cancer: defining its role and introducing the technique

  2014cited by this paper
• A comparison of carboplatin and paclitaxel with cisplatinum and 5-fluorouracil in definitive chemoradiation in esophageal cancer patients.

  2014cited by this paper
• Conventional stents versus stents loaded with (125)iodine seeds for the treatment of unresectable oesophageal cancer: a multicentre, randomised phase 3 trial.

  2014cited by this paper
• Prospective, randomized, multicenter, phase III study of fluorouracil, leucovorin, and irinotecan versus epirubicin, cisplatin, and capecitabine in advanced gastric adenocarcinoma: a French intergroup (Fédération Francophone de Cancérologie Digestive, Fédération Nationale des Centres de Lutte Contre

  2014cited by this paper
• Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial.

  2014cited by this paper
• Gefitinib for oesophageal cancer progressing after chemotherapy (COG): a phase 3, multicentre, double-blind, placebo-controlled randomised trial.

  2014cited by this paper
• The initial report of RTOG 0436: A phase III trial evaluating the addition of cetuximab to paclitaxel, cisplatin, and radiation for patients with esophageal cancer treated without surgery.

  2014cited by this paper
• Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trial.

  2014cited by this paper
• Combination of cisplatin/S-1 in the treatment of patients with advanced gastric or gastroesophageal adenocarcinoma: Results of noninferiority and safety analyses compared with cisplatin/5-fluorouracil in the First-Line Advanced Gastric Cancer Study.

  2013cited by this paper
• Imaging strategies in the management of oesophageal cancer: what’s the role of MRI?

  2013cited by this paper
• Clinical application of iodine-eluting stent in patients with advanced esophageal cancer

  2013cited by this paper
• Induction Chemotherapy or Chemoradiotherapy Followed by Radical Esophagectomy for T4 Esophageal Cancer: Results of a Prospective Cohort Study

  2013cited by this paper
• Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): a multicentre, phase 2/3 randomised trial.

  2013cited by this paper
• Chemotherapeutic options for gastroesophageal junction tumors.

  2013cited by this paper
• Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial.

  2013cited by this paper
• The feasibility of triple-drug chemotherapy combination in older adult patients with oesophagogastric cancer: a randomised trial of the Arbeitsgemeinschaft Internistische Onkologie (FLOT65+).

  2013cited by this paper
• Oesophageal carcinoma.

  2013cited by this paper
• Outcomes Associated with Surgery for T4 Esophageal Cancer

  2013cited by this paper
• Megestrol acetate for treatment of anorexia-cachexia syndrome.

  2013cited by this paper
• Palliative brachytherapy with or without primary stent placement in patients with oesophageal cancer, a randomised phase III trial.

  2013cited by this paper
• Oesophageal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

  2013cited by this paper
• Survival After Recurrent Esophageal Carcinoma Has Not Improved Over the Past 18 Years

  2013cited by this paper
• Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial

  2013cited by this paper
• Preoperative chemoradiotherapy for esophageal or junctional cancer.

  2012cited by this paper
• Palliative Stenting With or Without Radiotherapy for Inoperable Esophageal Carcinoma: A Randomized Trial

  2012cited by this paper
• A global assessment of the oesophageal adenocarcinoma epidemic

  2012cited by this paper
• Oligometastases treated with stereotactic body radiotherapy: long-term follow-up of prospective study.

  2012cited by this paper
• Nutrition Therapy Issues in Esophageal Cancer

  2012cited by this paper
• Propensity score-based comparison of long-term outcomes with 3-dimensional conformal radiotherapy vs intensity-modulated radiotherapy for esophageal cancer.

  2012cited by this paper
• Clinical study of concurrent chemoradiotherapy or radiotherapy alone for esophageal cancer patients with positive lymph node metastasis.

  2012cited by this paper
• Comparison of 2 expandable stents for malignant esophageal disease: a randomized controlled trial.

  2012cited by this paper
• Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone.

  2012cited by this paper
• Clinical practice and outcome of radiotherapy for esophageal cancer between 1999 and 2003: the Japanese Radiation Oncology Study Group (JROSG) Survey

  2012cited by this paper
• Randomized Comparison of Three Palliative Regimens Including Brachytherapy, Photodynamic Therapy, and APC in Patients With Malignant Dysphagia (CONSORT 1a) (Revised II)

  2011cited by this paper
• Oligometastases revisited

  2011cited by this paper
• Expandable stents for malignant esophageal disease.

  2011cited by this paper
• Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis.

  2011cited by this paper
• Definitive chemoradiation for oesophageal cancer--a standard of care in patients with non-metastatic oesophageal cancer.

  2011cited by this paper
• Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO).

  2011cited by this paper
• Chemoradiation for Esophageal Cancer: Institutional Experience With Three Different Regimens

  2011cited by this paper
• Treatment of T4 esophageal cancer. Definitive chemo-radiotherapy vs chemo-radiotherapy followed by surgery.

  2011cited by this paper
• Quality of life in patients with esophageal stenting for the palliation of malignant dysphagia.

  2011cited by this paper
• Effects of pain, fatigue, insomnia, and mood disturbance on functional status and quality of life of elderly patients with cancer.

  2011cited by this paper
• Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study.

  2011cited by this paper
• Nutritional support in patients with oesophageal cancer

  2010cited by this paper
• Cisplatin/Irinotecan Versus Carboplatin/Paclitaxel as Definitive Chemoradiotherapy for Locoregionally Advanced Esophageal Cancer

  2010cited by this paper
• Randomised, non-comparative phase II study of weekly docetaxel with cisplatin and 5-fluorouracil or with capecitabine in oesophagogastric cancer: the AGITG ATTAX trial

  2010cited by this paper
• Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.

  2010cited by this paper
• Role of esophageal stents in the nutrition support of patients with esophageal malignancy.

  2010cited by this paper
• Weekly docetaxel, cisplatin, and 5‐fluorouracil as initial therapy for patients with advanced gastric and esophageal cancer

  2010cited by this paper
• Adding external beam to intra-luminal brachytherapy improves palliation in obstructive squamous cell oesophageal cancer: a prospective multi-centre randomized trial of the International Atomic Energy Agency.

  2010cited by this paper
• The Use of Self-Expanding Stents in Esophageal and Gastroesophageal Junction Cancer Palliation: A Meta-Analysis and Meta-Regression Analysis of Outcomes

  2010cited by this paper
• WITHDRAWN. Combined chemotherapy and radiotherapy (without surgery) compared with radiotherapy alone in localized carcinoma of the esophagus.

  2010cited by this paper
• Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial.

  2010cited by this paper
• Definitive concomitant chemoradiotherapy with docetaxel and cisplatin in squamous esophageal carcinoma.

  2010cited by this paper
• Chemotherapy for advanced gastric cancer.

  2010cited by this paper
• Antireflux stent versus conventional stent in the palliation of distal esophageal cancer. A randomized, multicenter clinical trial

  2010cited by this paper
• Comparison of double‐layered and covered Niti‐S stents for palliation of malignant dysphagia

  2009cited by this paper
• Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial.

  2009cited by this paper
• A Randomized Controlled Clinical Trial of Palliative Therapies for Patients With Inoperable Esophageal Cancer

  2009cited by this paper
• The impact of primary tumour origins in patients with advanced oesophageal, oesophago-gastric junction and gastric adenocarcinoma--individual patient data from 1775 patients in four randomised controlled trials.

  2009cited by this paper
• Meta-analysis of the REAL-2 and ML17032 trials: evaluating capecitabine-based combination chemotherapy and infused 5-fluorouracil-based combination chemotherapy for the treatment of advanced oesophago-gastric cancer.

  2009cited by this paper
• Self-expanding plastic esophageal stents versus jejunostomy tubes for the maintenance of nutrition during neoadjuvant chemoradiation therapy in patients with esophageal cancer: a retrospective study.

  2009cited by this paper
• A fully-covered stent (Alimaxx-E) for the palliation of malignant dysphagia: a prospective follow-up study.

  2009cited by this paper

• Overexpression of GPER1 suppressed esophageal carcinoma growth via activating cAMP pathway

  2026cites this paper
• Identification of 2 Ubiquitin-Proteasome System-Related Subtypes in Esophageal Squamous Cell Carcinoma for Prognostic and Immunotherapeutic Response Prediction.

  2025cites this paper
• Clinofibrate Disrupts the SNORA80B/YTHDC1‐Driven M6A Modification to Suppress Cholesterol Metabolism and Cisplatin Resistance in ESCC

  2025cites this paper
• Unraveling the mechanisms of matrine in esophageal cancer treatment: insights from network pharmacology, bioinformatics, and molecular biology experiments.

  2025cites this paper
• Real-World Outcomes Between Perioperative Chemotherapy (FLOT) and Preoperative Concurrent Chemoradiotherapy (CROSS) in Localized Esophageal and Esophagogastric Junction Adenocarcinoma: A Retrospective Cohort Study

  2025cites this paper
• Clinical features, treatment and prognosis analysis of distant metastatic esophageal cancer

  2025cites this paper
• “You’re just in such crisis mode…frantic to get through the next day”: an interpretative phenomenological analysis of adjustment experiences among carers of patients with advanced oesophago-gastric cancer

  2025cites this paper
• Unraveling the power of radiomics: prediction and exploration of lymph node metastasis in stage T1/2 esophageal squamous cell carcinoma

  2025cites this paper
• Geriatric Nutritional Risk Index is an effective prognostic predictor for metastatic/recurrent or unresectable esophageal cancer receiving immunotherapy

  2025cites this paper
• Efficacy and Safety of Photodynamic Therapy Sequential Dose-Reduction Concurrent Chemoradiotherapy in Locally Advanced Obstructive Esophageal Carcinoma: A Propensity Score Matching Analysis.

  2025cites this paper
• Multi‐Omics Analysis of Aberrances and Functional Implications of IRF5 in Digestive Tract Tumours

  2025cites this paper
• Comparative Analysis of Concurrent Chemoradiotherapy Versus Chemotherapy Alone as First-Line Palliative Treatments for Advanced Esophageal Squamous Cell Carcinoma

  2024cites this paper
• The efficacy and safety of anlotinib plus PD-1 inhibitor in locally advanced/metastatic esophageal squamous cell carcinoma (ESCC) patients who progressed on prior immune checkpoint inhibitors (ICIs): a retrospective real-world study (NCT 04984096)

  2024cites this paper
• Molecular mechanisms underlying oesophageal cancer development triggered by chronic alcohol consumption

  2024cites this paper
• Esophagectomy may have a role in stage IV esophageal adenocarcinoma.

  2024cites this paper
• Inflammatory markers correlate with lymphocytes infiltrating and predict immunotherapy prognosis for esophageal cancer.

  2024cites this paper
• Ligand-centred phenotype-driven development of potent kinase inhibitors against oesophageal cancer

  2024cites this paper
• Comparing the prognosis of esophageal adenocarcinoma with bone and liver metastases: A competing risk analysis

  2024cites this paper
• Dronedarone inhibits the proliferation of esophageal squamous cell carcinoma through the CDK4/CDK6-RB1 axis in vitro and in vivo

  2024cites this paper
• METTL3-mediated upregulation of FAM135B promotes EMT of esophageal squamous cell carcinoma via regulating the Wnt/β-catenin pathway.

  2024cites this paper
• A review on comprehending immunotherapeutic approaches inducing ferroptosis: Managing tumour immunity

  2024cites this paper
• Comparing the Efficacy of Carboplatin plus 5-Fluorouracil, Cisplatin plus 5-Fluorouracil, and Best Supportive Care for Advanced Esophageal Squamous Cell Carcinoma: A Propensity Score Analysis from a Tertiary Hospital in Southern Thailand

  2024cites this paper
• Esophageal cancer

  2024cites this paper
• Induction immunotherapy plus chemotherapy followed by definitive chemoradiation therapy in locally advanced esophageal squamous cell carcinoma: a propensity-score matched study

  2024cites this paper
• Comprehensive analysis of m6A RNA methylation regulators in esophageal carcinoma

  2024cites this paper
• Circ_0024108 promotes the progression of esophageal cancer cells

  2023cites this paper
• Efficacy and safety of anti-PD-1 antibody plus chemoradiotherapy in locally advanced esophageal squamous cancer

  2023cites this paper
• Management of Esophageal Squamous Cell Carcinoma With Esophageal Stent Placement in an Elderly Patient With Dysphagia

  2023cites this paper
• A Functional Stent Encapsulating Radionuclide in Temperature‐Memory Spiral Tubes for Malignant Stenosis of Esophageal Cancer

  2023cites this paper
• Nimotuzumab plus concurrent chemo-radiotherapy in unresectable locally advanced oesophageal squamous cell carcinoma (ESCC): interim analysis from a Phase 3 clinical trial

  2023cites this paper
• Radiotherapy for Advanced Esophageal Cancer: from Palliation to Curation

  2023cites this paper
• Induction immunochemotherapy followed by radiotherapy for patients with unresectable locally advanced or metastatic esophageal cancer: A propensity score-matched analysis.

  2023cites this paper
• Long-term health-related quality of life in patients with advanced esophagogastric cancer receiving first-line systemic therapy

  2023cites this paper
• NUMA1 modulates apoptosis of esophageal squamous cell carcinoma cells through regulating ASK1-JNK signaling pathway

  2023cites this paper
• EXOC3L1: A Novel Prognostic Biomarker Correlated with Immune Infiltration in Esophageal Squamous Cell Carcinoma

  2023cites this paper
• Role of ferroptosis in esophageal cancer and corresponding immunotherapy

  2023cites this paper
• Surgical outcome and prognosis of patients with spinal metastasis from esophageal cancer: the experience from a single center.

  2023cites this paper
• An artificial neural network-based radiomics model for predicting the radiotherapy response of advanced esophageal squamous cell carcinoma patients: a multicenter study

  2023cites this paper
• Radiotherapy combined with immune checkpoint inhibitors in locally advanced/metastatic esophageal squamous cell carcinoma: clinical trials, efficacy and future directions

  2023cites this paper
• SGK3 overexpression correlates with a poor prognosis in endoscopically resected superficial esophageal squamous cell neoplasia: A long-term study

  2023cites this paper
• High-dose versus standard-dose radiotherapy in concurrent chemoradiotherapy for inoperable esophageal cancer: a systematic review and meta-analysis.

  2023cites this paper
• The effect of Andrographis paniculata water extract on palliative management of metastatic esophageal squamous cell carcinoma—A phase II clinical trial

  2023cites this paper
• CircABCA13 acts as a miR‐4429 sponge to facilitate esophageal squamous cell carcinoma development by stabilizing SRXN1

  2023cites this paper
• Local Ablative Treatment Improves Survival in ESCC Patients With Specific Metastases, 2010–2016: A Population-Based SEER Analysis

  2022cites this paper
• Camrelizumab plus apatinib as second-line treatment for advanced oesophageal squamous cell carcinoma (CAP 02): a single-arm, open-label, phase 2 trial.

  2022cites this paper
• Reduction of esophageal stent migration rate with a novel over-the-scope fixation device.

  2022cites this paper
• Update on Management of Squamous Cell Esophageal Cancer

  2022cites this paper
• Chemotherapy predictors and a time-dependent chemotherapy effect in metastatic esophageal cancer

  2022cites this paper
• Prognostic significance of platelet-to-albumin ratio in patients with esophageal squamous cell carcinoma receiving definitive radiotherapy

  2022cites this paper
• Long noncoding RNA SNHG17: a novel molecule in human cancers

  2022cites this paper
• SOX17-mediated MALAT1-miR-199a-HIF1α axis confers sensitivity in esophageal squamous cell carcinoma cells to radiotherapy

  2022cites this paper
• The Evaluation of a SEER-Based Nomogram in Predicting the Survival of Patients Treated with Neoadjuvant Therapy Followed by Esophagectomy

  2022cites this paper
• Anti-reflux versus conventional self-expanding metal stents in the palliation of esophageal cancer: A systematic review and meta-analysis

  2022cites this paper
• Regional Chemotherapy Is a Valuable Second-Line Approach in Metastatic Esophageal Cancer after Failure to First-Line Palliative Treatment

  2022cites this paper
• Prevalence and Factors Associated with Palliative Care Utilization among Hospitalized Patients with Esophageal Cancer in the United States

  2022cites this paper
• A machine learning model predicting candidates for surgical treatment modality in patients with distant metastatic esophageal adenocarcinoma: A propensity score-matched analysis

  2022cites this paper
• CircFNDC3B knockdown restrains the progression of oesophageal squamous cell carcinoma through miR‐214‐3p/CDC25A axis

  2022cites this paper
• Real-World Efficacy and Safety of Sintilimab-Based Regimens against Advanced Esophageal Cancer: A Single-Center Retrospective Observational Study

  2022cites this paper
• Recent advances in multidisciplinary therapy for adenocarcinoma of the esophagus and esophagogastric junction

  2022cites this paper
• Recent Developments in the Significant Effect of mRNA Modification (M6A) in Glioblastoma and Esophageal Cancer

  2022cites this paper
• Characteristics and response to next‐generation sequencing‐guided therapy in locally advanced or metastatic esophageal cancer

  2022cites this paper
• Endoscopic Management of Esophageal Cancer.

  2022cites this paper
• Nomogram Based on Monocyte-to-Lymphocyte Ratio to Predict Survival of Unresectable Esophageal Squamous Cell Carcinoma Who Receive First-Line PD-1/PD-L1 Inhibitors Combined with Chemotherapy

  2022cites this paper
• TET3 governs malignant behaviors and unfavorable prognosis of esophageal squamous cell carcinoma by activating the PI3K/AKT/GSK3β/β-catenin pathway

  2022cites this paper
• Best Supportive Care of the Patient with Oesophageal Cancer

  2022cites this paper
• Circular RNA AKT3 governs malignant behaviors of esophageal cancer cells by sponging miR-17-5p

  2021cites this paper
• Severe lymphopenia acquired during chemoradiotherapy for esophageal cancer: incidence and external validation of a prediction model.

  2021cites this paper
• Improving Access to Self-Expanding Metal Stents for Patients With Esophageal Cancer in Eastern Africa: A Stepwise Implementation Strategy

  2021cites this paper
• Understanding Existential Anxiety and the Soothing Nature of Nostalgia in Life With Incurable Esophageal Cancer

  2021cites this paper
• ALKBH5 Is Lowly Expressed in Esophageal Squamous Cell Carcinoma and Inhibits the Malignant Proliferation and Invasion of Tumor Cells

  2021cites this paper
• Effectiveness and Safety of Targeted Agents Combined With Chemoradiotherapy for the Treatment of Esophageal Cancer: A Network Meta-Analysis

  2021cites this paper
• Ultrasound-stimulated microbubbles contributes to radiotherapy in esophageal carcinoma.

  2021cites this paper
• Development of immune gene pair-based signature predictive of prognosis and immunotherapy in esophageal cancer

  2021influential citation
• MicroRNA-124 inhibits proliferation and metastasis of esophageal cancer via negatively regulating NRP1.

  2021cites this paper
• Targeting integrin αvβ3 with indomethacin inhibits patient‐derived xenograft tumour growth and recurrence in oesophageal squamous cell carcinoma

  2021cites this paper
• Identification of HLA-A2-Restricted Mutant Epitopes from Neoantigens of Esophageal Squamous Cell Carcinoma

  2021cites this paper
• LncRNA SNHG17 regulates cell proliferation and invasion by targeting miR-338-3p/SOX4 axis in esophageal squamous cell carcinoma

  2021cites this paper
• Recent advances of m6A methylation modification in esophageal squamous cell carcinoma

  2021cites this paper
• Surgical and interventional treatment options in unresectable gastrointestinal cancer

  2021cites this paper
• Circular RNA hsa_circ_0000277 sequesters miR-4766-5p to upregulate LAMA1 and promote esophageal carcinoma progression

  2021cites this paper
• Association between unintentional splenic radiation and lymphopenia and high neutrophil/lymphocyte ratio after radiotherapy in patients with esophageal cancer

  2021cites this paper
• Comparative efficacy of treatments for previously treated patients with advanced esophageal and esophagogastric junction cancer: A network meta-analysis

  2021cites this paper
• Surgeons' Role in Local Palliation of Esophageal Cancer.

  2021cites this paper
• CDCA2 promotes tumorigenesis and induces radioresistance in oesophageal squamous cell carcinoma cells

  2021cites this paper
• Role of surgery in the management of synchronous metastatic esophageal cancer

  2021cites this paper
• Periplogenin suppresses the growth of esophageal squamous cell carcinoma in vitro and in vivo by targeting STAT3

  2021cites this paper
• Palliation of malignant dysphagia: stent or radiotherapy?

  2021cites this paper
• Rps15a Imparts Chemoresistance by Regulating Cd44 Expression and Cell Stemness in Esophageal Squamous Cell Carcinoma

  2021cites this paper
• UBE2T Contributes to the Prognosis of Esophageal Squamous Cell Carcinoma

  2021cites this paper
• Remarkable inhibition effects of afatinib alone or combining with paclitaxel in esophageal squamous cell carcinoma

  2021cites this paper
• Number 3 January 21 , 2021 ABOUT COVER

  2021cites this paper
• KEYNOTE-975 study design: a Phase III study of definitive chemoradiotherapy plus pembrolizumab in patients with esophageal carcinoma

  2021cites this paper
• Long non-coding RNA HAGLROS regulates the proliferation, migration, and apoptosis of esophageal cancer cells via the HAGLROS-miR-206-NOTCH3 axis.

  2021cites this paper
• CMAR_A_230274 7467..7474

  2020cites this paper
• Robotic-assisted minimally invasive esophagectomy: past, present and future.

  2020cites this paper
• Prediction of severe lymphopenia during chemoradiotherapy for esophageal cancer: development and validation of a pretreatment nomogram.

  2020cites this paper
• High Mean Corpuscular Volume as a Predictor of Poor Overall Survival in Patients with Esophageal Cancer Receiving Concurrent Chemoradiotherapy

  2020cites this paper
• Construction and Validation of a 7-Immune Gene Model for Prognostic Assessment of Esophageal Carcinoma

  2020cites this paper
• Meta-analysis of efficacy and complications of intraluminal radioactive stent and common covered stent in treatment of advanced esophageal cancer

  2020cites this paper
• Novel T7-Modified pH-Responsive Targeted Nanosystem for Co-Delivery of Docetaxel and Curcumin in the Treatment of Esophageal Cancer

  2020cites this paper